Ironwood Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:I76 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 Nov 24	Sell€42,465	Sravan Emany	Individual	11,001	€3.86
18 Nov 24	Sell€20,690	Andrew Davis	Individual	5,360	€3.86
12 Aug 24	Sell€12,133	Ronald Silver	Individual	3,107	€3.90
12 Aug 24	Sell€38,698	John Minardo	Individual	9,910	€3.90
07 Jun 24	Sell€478,970	Catherine Moukheibir	Individual	80,000	€6.12
20 May 24	Sell€103,354	John Minardo	Individual	17,404	€5.94
20 May 24	Sell€95,776	Michael Shetzline	Individual	16,128	€5.94
20 May 24	Sell€401,551	Thomas McCourt	Individual	67,618	€5.94
20 May 24	Sell€134,953	Andrew Davis	Individual	22,725	€5.94
06 Mar 24	Buy€55,225	Jon Duane	Individual	6,920	€7.98
04 Mar 24	Buy€92,269	Sravan Emany	Individual	10,684	€8.64
12 Feb 24	Sell€2,506,391	Thomas McCourt	Individual	177,164	€14.15
12 Feb 24	Sell€139,294	Andrew Davis	Individual	9,846	€14.15
12 Feb 24	Sell€546,340	Michael Shetzline	Individual	38,618	€14.15
12 Feb 24	Sell€670,299	John Minardo	Individual	47,380	€14.15
12 Feb 24	Sell€111,877	Ronald Silver	Individual	7,908	€14.15

Insider Trading Volume

Insider Buying: I76 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of I76?
Owner Type	Number of Shares	Ownership Percentage
State or Government	64,874	0.0381%
Individual Insiders	3,163,651	1.86%
Hedge Funds	33,187,198	19.5%
Institutions	133,930,167	78.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 87.07% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.3%	BlackRock, Inc.	22,919,857	€51.7m	0.19%	no data
13.8%	The Vanguard Group, Inc.	22,038,097	€49.7m	2.2%	no data
10.2%	Sarissa Capital Management LP	16,390,000	€37.0m	0%	14.92%
7.33%	Pacer Advisors, Inc.	11,730,771	€26.5m	4%	0.1%
6.2%	State Street Global Advisors, Inc.	9,919,865	€22.4m	7.32%	no data
5.37%	Renaissance Technologies LLC	8,597,198	€19.4m	0.3%	0.05%
5.12%	Armistice Capital LLC	8,200,000	€18.5m	5.13%	0.69%
3.16%	LSV Asset Management	5,051,601	€11.4m	-16.8%	0.04%
2.77%	Braidwell LP	4,438,232	€10.0m	0%	0.72%
2.67%	Jacobs Levy Equity Management Inc	4,265,100	€9.6m	-2.14%	0.06%
2.3%	Kynam Capital Management, LP	3,685,563	€8.3m	124%	1.07%
2.3%	Morgan Stanley, Investment Banking and Brokerage Investments	3,672,661	€8.3m	-8.72%	no data
2.06%	Geode Capital Management, LLC	3,293,542	€7.4m	-2.34%	no data
1.19%	Charles Schwab Investment Management, Inc.	1,904,271	€4.3m	0%	no data
0.94%	Northern Trust Global Investments	1,506,148	€3.4m	2.01%	no data
0.91%	Jupiter Fund Management Plc	1,448,435	€3.3m	0%	0.02%
0.87%	Norges Bank Investment Management	1,393,077	€3.1m	0%	no data
0.79%	Two Sigma Advisers, LP	1,260,500	€2.8m	5.13%	0.01%
0.76%	UBS Asset Management AG	1,216,609	€2.7m	-43.4%	no data
0.75%	Argenta Asset Management SA	1,207,997	€2.7m	0%	0.09%
0.7%	Saturn V Capital Management LP	1,120,409	€2.5m	0.59%	1.9%
0.67%	Goldman Sachs Group, Investment Banking and Securities Investments	1,080,112	€2.4m	-26.6%	no data
0.66%	Deutsche Asset & Wealth Management	1,063,199	€2.4m	1.53%	no data
0.62%	Stonepine Capital Management LLC	1,000,000	€2.3m	1,980%	1.29%
0.58%	Millennium Management LLC	925,872	€2.1m	-30.3%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/02 12:03
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 35 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg
David Maris	BMO Capital Markets Equity Research